A randomized open-label clinical trial of an anti-HPV biological dressing (JB01-BD) administered intravaginally to treat high-risk HPV infection.
Currently, there is no specific antiviral therapy for HPV infection. We conducted a randomized open-label clinical trial of JB01-BD, an anti-HPV biological dressing from Shanxi Jinbo Pharmaceutical Co., Ltd., China, for treatment of HPV infection. Seventy-seven women with cervical infection by high-risk HPV were randomly divided into a treatment group and a non-treatment group. After treatment, about 60.5% (23/38) of HPV-positive women in the treatment group became HPV-negative compared with 13.5% (5/37) of women in the non-treatment group becoming HPV-negative (P < 0.001). These data suggest that JB01-BD is an effective topical biological agent for the treatment of cervical HPV infection.
First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China.
Xuetao
X
Guo
Shanxi Medical University, Shanxi 030001, China.
Lixia
L
Qiu
Chinese PLA General Hospital, Beijing 100036, China.
Yue
Y
Wang
Second Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China.
Yonghong
Y
Wang
Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Public Health Clinical Center and Shanghai Medical College, Fudan University, Shanghai 200032, China.
Qian
Q
Wang
Chinese PLA General Hospital, Beijing 100036, China.
Lei
L
Song
Chinese PLA General Hospital, Beijing 100036, China.
Yali
Y
Li
Chinese PLA General Hospital, Beijing 100036, China.
Ke
K
Huang
Chinese PLA General Hospital, Beijing 100036, China.
Xinxin
X
Du
Chinese PLA General Hospital, Beijing 100036, China.
Wensheng
W
Fan
Chinese PLA General Hospital, Beijing 100036, China.
Shufang
S
Jiang
Xinxiang Central Hospital Affiliated with Medical School, Henan 453000, China.
Qianqing
Q
Wang
Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Public Health Clinical Center and Shanghai Medical College, Fudan University, Shanghai 200032, China.
Haoyang
H
Li
Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Beijing 100730, China.
Yi
Y
Yang
Chinese PLA General Hospital, Beijing 100036, China.
Yuanguang
Y
Meng
National Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China.
Yun
Y
Zhu
Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Public Health Clinical Center and Shanghai Medical College, Fudan University, Shanghai 200032, China.
Lu
L
Lu
Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, Shanghai Public Health Clinical Center and Shanghai Medical College, Fudan University, Shanghai 200032, China; Lindsley F. Kimball Research Institute, New York Blood Center, New York, NY 10065, USA. Electronic address: shibojiang@fudan.edu.cn.
Shibo
S
Jiang
D000282:Administration, Intravaginal; D001684:Biological Dressings; D002584:Cervix Uteri / Q000821:virology; D002681:China; D005260:Female; D006801:Humans; D027383:Papillomaviridae / Q000302:isolation & purification; D030361:Papillomavirus Infections / Q000628:therapy*; D016896:Treatment Outcome
Antiviral therapy; Cervical cancer; Clinical trial; Human papilloma virus (HPV)